Abstract: Clonal hematopoiesis of indeterminate potential （ CHIP）  is a condition characterized by the expansion of hematopoietic stem cells with uncertain pathogenic potential， which is associated with aging. Epidemiological studies have indicated that CHIP  is  linked  to  an  increased  risk  of  hematological  disorders  and  is  closely  related  to  kidney  diseases， including a  decline  in  kidney  function，  acute  kidney  injury  （ AKI ），  chronic  kidney  disease  （ CKD ），  and  diabetic nephropathy. CHIP⁃related mutations， such as TET2， JAK2， ASXL1， etc.， can activate inflammation⁃associated signaling pathways [ such  as  the  NOD⁃like  recepror  pyrin  domain⁃containing  3  （ NLRP3）  inflammasomes，  absent  in  melanoma  2 （ AIM2）， etc.]，  induce  local  inflammatory  responses，  and  promote  kidney  fibrosis.  This  article  aims  to  discuss  various aspects  of  CHIP  including  its  epidemiology，  the  relationship  with  kidney  diseases，  detection  methods，  management strategies， and future  prospects，  with  a  focus  on  exploring  the  relationship  and  research  progress  of  CHIP  with  kidney diseases. The  objective  is  to  provide  a  theoretical  basis  for  the  prevention  and  treatment  of  kidney  diseases  and  the development and application of anti⁃inflammatory drugs.

Key words: clonal hematopoiesis of indeterminate potential ,  ,  kidney disease ,  ,  inflammation ,  ,  acute kidney injury chronic kidney disease